Arm & Hammer Animal and Food Production

Arm & Hammer Highlights Latest Trial Results at EuroTier 2016

At a research update and product training session during EuroTier 2016, Arm & Hammer highlighted its latest trial results for its yeast product CELMANAXTM, among other products.

As presented by Dr. Elliot Block, research fellow at Arm & Hammer, trials conducted in breeders and broilers saw 'elimination' of Salmonella and E. coli, while trials in layers saw a reduction of contamination of those bacteria in eggs.

For swine, several non-conclusive trials in improvements in FCR and body weight gain were reported.

For beef and dairy cattle, trial results were generally conclusive, with reduced cases of HBS (Haemorrhagic Bowel Syndrome, a disease with a yet unknown cause) seen.

Interestingly, Dr. Block pointed out that while CELMANAX does not bind DON, a mycotoxin, the product was effective in reducing cell damage (Cytotoxicity Index) caused by DON. CELMANAX was also effective against the mycotoxins ZEAR, T-2 and FUM B1. Further research would be conducted to determine the mechanism or mechanisms which CELMANAX uses to work against those mycotoxins.

Specifically for dairy cattle, Dr. Block also presented positive trial results for BIO-CHLORTM, a DCAD (Dietary Cation-Anion Balance) product, and that for ESSENTIOMTM, an Omega-3 and Omega-6 essential fatty acid product.

Find a Distributor
Find a Sales Representative

Please select a country